Table 1 Characteristics of 76 patients with severe sepsis and septic shock according to discontinuation or not of ongoing statin therapy at ICU admission
Discontinuation group (n = 32) | Continuation group (n = 44) | P value | Absolute standardized difference* (%) | |
|---|---|---|---|---|
Age, years | 71.1 (61.7-78.7) | 72.9 (62.3-79.6) | 0.66 | 7.7 |
Male gender, n (%) | 26 (81%) | 33 (75%) | 0.52 | 15.0 |
SAPS II at ICU admission | 44 (34-62) | 40 (32-51) | 0.15 | 37.5 |
SOFA at ICU admission | 8 (5-10) | 7 (4-9) | 0.21 | 31.0 |
Mac Cabe classification,** n (%) | 0.13 | 6.8 | ||
Nonfatal or no underlying disease | 15 (47%) | 18 (41%) | ||
Ultimately fatal underlying disease | 13 (41%) | 25 (57%) | ||
Rapidly fatal underlying disease | 4 (13%) | 1 (2%) | ||
Prior statin therapy duration, years (n = 67) | 3.5 (1.0-6.3) | 5.0 (1.4-7.6) | 0.26 | 31.5 |
Type of statin, n (%) | 0.28 | 15.4 | ||
Atorvastatin | 13 (41%) | 18 (41%) | ||
Pravastatin | 9 (28%) | 15 (34%) | ||
Simvastatin | 10 (31%) | 7 (16%) | ||
Rosuvastatin | 0 (0%) | 3 (7%) | ||
Fluvastatin | 0 (0%) | 1 (2%) | ||
Surgery before ICU admission, n (%) | 11 (34%) | 5 (11%) | 0.02 | 56.1 |
Septic shock at ICU admission, n (%) | 19 (59%) | 16 (34%) | 0.05 | 46.7 |